Immunic Acquires 4SC’s Immunology Portfolio

November 14th, 2016
Posted by


After announcing the the closure of Series A funding with $19.6 million, Immunic recently acquired 4SC’s immunology portfolio. The acquisition adds two promising drug development programs to the biotech startup’s portfolio to treat immune and autoimmune diseases.

Founded in 2016 by Manfred Groppel and Popper’s senior advisor, Dr. Andreas Muehler, Immunic develops pharmaceuticals in the immunology space, in particular for autoimmune diseases or diseases that have an important immunology component in their pathogenesis.

We are excited about the potential impact of this acquisition which will start with a clinical study involving Crohn’s patients, and are continuing to track these and other developments at the intersection of biotechnology and immunology.

Read more about the acquisition.


Like this content? Don’t miss an update.

About the Author:

I founded Popper and Company with Ken Walz more than ten years ago to address inefficiencies in health care by helping life science companies develop and commercialize new technology. Today, the members of our growing team leverage their extensive knowledge of the tools and trends shaping all aspects of health care and its participants. Send me an email.